Drawing for LUNDBECK INSTITUTE

USPTO serial 88140927

LUNDBECK INSTITUTE

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
MIDDLETON, BERNICE L
Law office
TMEG LAW OFFICE 106 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LUNDBECK INSTITUTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Claudia A. Smith

CLAUDIA A. SMITH WHITE & CASE LLP1221 AVENUE OF THE AMERICASTRADEMARK DEPARTMENTNEW YORK, NY 10020

Goods and services

ClassDescriptionStatusFirst use
005Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and chemical dependency; diagnostic agents, reagents, preparations and substances for medical purposesACTIVE—
009Downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, disease awareness, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine, medicine, pharmaceuticals, disorders, diseases, clinical or medical treatment and prevention; software for medical and pharmaceutical information, education and sales activities; software for analyzing medical and pharmaceutical information and disease awareness; software, namely, application software for mobile devices for analyzing medical and pharmaceutical information; apparatus and instruments for analyzing medical and pharmaceutical information in the field of research and development, science, clinical studies, medical clinical tests and trials, diagnostic medicine, pharmaceuticals, disorders, diseases, treatment and prevention; electronic downloadable publications, namely, magazines, journals, teaching and educational materials in the field of pharmaceutical research and development, science, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine related to clinical or medical treatment and prevention; application software for mobile devices for the assessment of cognitive functions; ; downloadable software for assessment of cognitive functions; software for use in diagnosing, managing, monitoring, assessing, controlling and examining psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependencyACTIVE—
016Paper, cardboard, paper labels, printed publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, science, medical clinical studies, pharmaceutical tests and trials, diagnostic medicine, medicine, pharmaceuticals, disorders, diseases, treatment and preventionACTIVE—
041Educational services, namely, conducting seminars in the field of pharmaceuticals and disease awareness; providing of training in the field of pharmaceuticals and disease awareness; arranging and conducting seminars, conferences, symposiums, training workshops and courses in the field of pharmaceuticals and disease awareness; educational training services in the fields of pharmaceutical research and development, medical clinical studies, pharmaceutical tests and trials and diagnostic medicine related to the treatment and prevention of diseases and disorders; providing the aforementioned services electronically, on-line, via cable or Internet or other electronic media; arranging and conducting expert forums, namely, on-line training programs in the field of pharmaceuticals; providing on-line, non-downloadable publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material in the field of pharmaceutical research and development, science, medical clinical studies in the field of pharmaceutical tests and trials, diagnostic medicine, pharmaceuticals, disorders, disease awareness, treatment and prevention related to the assessment of cognitive functions; providing educational assessment services in the field of cognitive functions through on-line non-downloadable screening toolsACTIVE—
042Pharmaceutical research and development; scientific and technological services, namely, scientific testing and research related to medical disorders, medical diseases and medical prevention; scientific and technological services, namely, scientific testing and research related to the central nervous system and central nervous system related disorders, pharmaceuticals and disease awareness; medical and clinical research, namely, clinical research and conducting clinical trials for others in the field of pharmaceuticals; diagnostic research and tests in the field of pharmaceutical research; providing online non-downloadable screening software for assessing cognitive functionsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 15, 2019MAB1ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT—
Mar 15, 2019ABN1ABANDONMENT - EXPRESS MAILED—
Mar 14, 2019EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Nov 1, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 1, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 26, 2018DOCKASSIGNED TO EXAMINER—
Oct 11, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 6, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance